NX-13
目录号 : KG12232
CAS No. : 2389235-01-0
纯度 : 98%
NX-13 is a first-in-class, orally active and gut-restricted agent that selectively targets and activates the NLRX1 pathway to induce immunometabolic changes. NX-13 results in lower inflammation and responses in inflammatory bowel disease. NX-13 can be used for the research of crohn’s disease and ulcerative colitis.
NX-13 (0, 500, or 1000 mg/kg; oral gavage; 7 days) reduces ALP levels.NX-13 (1 and 10 mg/kg; oral gavage; 0~24 hours) reaches the distal gastrointestinal tract.
Other Forms of Rapamycin:
KKL Med 的所有产品和服务仅用于科学研究,不能被用于人体,兽医,我们也不向个人提供产品和服务。
KKL 顾客使用本产品发表的 0 篇科研文献
暂无科研文献
分子式 |
C24H21N3O3
|
分子量 |
399.44
|
CAS号 |
2389235-01-0
|
储存方式 |
Powder |
-20°C |
3 years |
|
4°C |
2 years |
In solvent |
-80°C |
6 months |
|
-20°C |
1 month |
|